Exelixis, Inc. (LON:0IJO)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 9.41B +24.7% |
| Revenue (ttm) | 1.84B +9.2% |
| Net Income | 648.65M +42.9% |
| EPS | 2.40 +53.4% |
| Shares Out | n/a |
| PE Ratio | 14.51 |
| Forward PE | 12.72 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,437 |
| Open | 50.60 |
| Previous Close | 51.80 |
| Day's Range | 50.10 - 51.50 |
| 52-Week Range | 33.81 - 57.49 |
| Beta | 0.42 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Exelixis
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep... [Read more]
Financial Performance
In 2025, Exelixis's revenue was $2.32 billion, an increase of 6.98% compared to the previous year's $2.17 billion. Earnings were $782.57 million, an increase of 50.13%.
Financial numbers in USD Financial StatementsNews
EXEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Exelixis
Exelixis lowered and narrowed its full-year 2026 revenue guidance, citing a slower-than-expected neuroendocrine-tumor ramp -- and shares declined. SueWallSt notifies investors of a pending investigati...
Leerink downgrades Exelixis to Market Perform following Q2 results
As previously reported, Leerink analyst Andrew Berens downgraded Exelixis (EXEL) to Market Perform from Outperform with a price target of $52, down from $55, following Q2 results that missed expectati...
Exelixis downgraded to Market Perform from Outperform at Leerink
Leerink downgraded Exelixis (EXEL) to Market Perform from Outperform with a $52 price target
Exelixis price target raised to $51 from $47 at Stifel
Stifel analyst Stephen Willey raised the firm’s price target on Exelixis (EXEL) to $51 from $47 and keeps a Hold rating on the shares.
Exelixis price target lowered to $52 from $56 at Truist
Truist analyst Gregory Renza lowered the firm’s price target on Exelixis (EXEL) to $52 from $56 and keeps a Hold rating on the shares. Exelixis reported a mixed Q2 with…
Exelixis reports Q2 non-GAAP EPS 91, consensus 86c
Reports Q2 revenue $628.7M, consensus $636.15M. “Exelixis (EXEL) continues to execute across the key pillars of our business, positioning the company to deliver on our strategic objectives for 2026 an...
Exelixis lowers FY26 revenue outlook to $2.5B-$2.55B from $2.525B-$2.625B
Consensus $2.6B.
Exelixis Earnings Call Transcript: Q2 2026
Q2 2026 revenues grew to $629M, with CABO franchise up 10% year-over-year and global revenues up 13%. Zanza's CRC NDA is under review, with multiple pivotal trials advancing and a robust pipeline supporting long-term growth. Guidance was lowered due to a slower NET ramp.
Exelixis Earnings release: Q2 2026
Exelixis released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Exelixis Quarterly report: Q2 2026
Exelixis has published its Q2 2026 quarterly earnings report on August 5, 2026.
Exelixis Slides: Q2 2026
Exelixis has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2026, provided an update on progress toward achieving key corporate objective...
Exelixis price target raised to $53 from $50 at Morgan Stanley
Morgan Stanley analyst Sean Laaman raised the firm’s price target on Exelixis (EXEL) to $53 from $50 and keeps an Equal Weight rating on the shares. Q2 earnings should reinforce…
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2026 financial results will be released on Wednesday, August 5, 2026 after the markets close. At...
Exelixis price target raised to $49 from $45 at Barclays
Barclays analyst Etzer Darout raised the firm’s price target on Exelixis (EXEL) to $49 from $45 and keeps an Equal Weight rating on the shares. The firm adjusted the price…
Exelixis price target raised to $49 from $40 at Wells Fargo
Wells Fargo raised the firm’s price target on Exelixis (EXEL) to $49 from $40 and keeps an Equal Weight rating on the shares. The firm updated its model ahead of…
Exelixis price target raised to $56 from $54 at Truist
Truist raised the firm’s price target on Exelixis (EXEL) to $56 from $54 and keeps a Hold rating on the shares as part of a broader research note updating the…
Exelixis price target raised to $46 from $43 at RBC Capital
RBC Capital raised the firm’s price target on Exelixis (EXEL) to $46 from $43 and keeps a Sector Perform rating on the shares as part of a broader research note…
Exelixis price target raised to $52 from $43 at UBS
UBS analyst Ashwani Verma raised the firm’s price target on Exelixis (EXEL) to $52 from $43 and keeps a Neutral rating on the shares. The stock is resilient, but the…
Exelixis assumed with Hold from Buy at Truist
Truist analyst Gregory Renza downgraded Exelixis (EXEL) to Hold from Buy with a price target of $54, up from $51, after assuming coverage of the name. The company’s recent non-liver…
Exelixis announces results from final analysis of phase 3 STELLAR-303 trial
Exelixis (EXEL) announced results from the final analysis of the dual primary endpoint of overall survival in the subset of patients without active liver metastases in the phase 3 STELLAR-303…
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the dual primary endpoint of overall survival (OS) in the subset of patients without ...
Exelixis Hits High on Growing Sales, Institutional Inflows
Drug adoption and a strong pipeline see institutions send Exelixis, Inc. (EXEL) shares to all-time highs.
Exelixis Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is evolving from a single to a multi-franchise model, maximizing cabo's value while preparing for zanza's launch in CRC. Robust clinical data and a focused commercial strategy drive growth, with multiple pivotal studies and early-stage assets supporting future expansion.
Exelixis Transcript: Jefferies Global Healthcare Conference 2026
The company is evolving to a franchise model, leveraging past learnings to position Zanza as a future standard of care in RCC and other cancers. Multiple pivotal studies and new diagnostics are expanding market opportunities, while capital allocation remains balanced between R&D, BD, and share buybacks.